

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

ANNOUNCEMENT

PROPOSED AMENDMENTS TO THE ARTICLES

The Company is a listed company on the Hong Kong Stock Exchange (Listing Rules).

The Company is a public company listed on the Hong Kong Stock Exchange. The Company is a public company listed on the Hong Kong Stock Exchange. The Company is a public company listed on the Hong Kong Stock Exchange.

The Board of Directors (Board) of the Company is responsible for the proposed amendments to the Articles of Association (Articles) of the Company.

On February 14, 2023, the State Council (State Council) of the PRC issued a decision (Decision) regarding the abolition of certain administrative regulations and documents (Decision). The decision is effective from the date of issuance. The decision is effective from the date of issuance. The decision is effective from the date of issuance.

I a Ma da P C a L O a (《關於執
行 到境外上市公司章程必備條款 的通知》). T D c a d T a M a
(c c , **New PRC Regulations**) a b c c Ma c 31, 2023.